

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and  
Waivers under Section 712(c)(2)(B) of the Food, Drugs, and Cosmetic Act  
and 18 U.S.C. §208 Particular Matter Waiver**

Ralph D'Agostino, Ph.D.

**Committees:** Nonprescription Drugs Advisory Committee

**Meeting Date:** December 14, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the safety and effectiveness of phenylephrine hydrochloride and phenylephrine bitartrate as Over-The-Counter (OTC) oral nasal decongestants, I am eligible to receive waivers under Section 18 U.S.C. §208 (b)(3) and 712(c)(2)(B).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Data Safety Monitoring Board	Affected firm	From \$10,001 to \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of this interest the waivers are not valid.

\_\_\_\_\_  
/S/  
Signature of SGE

\_\_\_\_\_  
November 6, 2007  
Date